Kusajili – Clinical trials directory

Result of your search per specialist: Astellas Pharma Europe B.V., Medical Clinical Development

Woman and Man Max 99 years
Astellas Pharma Europe B.V., Medical Clinical Development Update Il y a 4 ans

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement su...

Country None
organs None
Specialty None

Closed trial

More information